Document Detail

Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.
MedLine Citation:
PMID:  15670539     Owner:  NLM     Status:  MEDLINE    
A large proportion of patients who have erectile dysfunction also have coronary artery disease (CAD). In these patients, nitrate therapy is a contraindication to the use of sildenafil. To assess whether the metabolic anti-ischemic agent, trimetazidine, is effective in controlling episodes of myocardial ischemia during sexual activity in patients who have CAD and use long-term nitrate therapy, we studied 38 men (57 +/- 6 years of age) who had proved CAD. Patients underwent 24-hour ambulatory electrocardiographic monitoring at baseline, after 1 week of oral nitrate therapy (20 mg 3 times a day), and after 1 week of trimetazidine (20 mg 3 times a day). Patients were asked to engage in >/=1 session of sexual intercourse during each session of ambulatory electrocardiographic monitoring. They were instructed to take sildenafil (100 mg) 1 hour before sexual intercourse performed at baseline and during therapy with trimetazidine and sildenafil or placebo (blinded) during therapy with nitrates. A decrease in total ischemic burden was observed with nitrates and trimetazidine compared with baseline (-3 +/- 1.2 episodes/patient/24 hours vs -5 +/- 1.3 episodes/patient/24 hours and -6 +/- 5 min/patient/24 hours vs -8 +/- 3 min/patient/24 hours, p <0.01 for nitrates and trimetazidine vs baseline). Trimetazidine plus sildenafil was more effective in controlling episodes of myocardial ischemia during sexual activity than nitrates alone (-45 +/- 11% vs -18 +/- 7%, p <0.04). In conclusion, in patients who have CAD, combination therapy with sildenafil and trimetazidine is more effective than nitrate therapy in the control of ischemic episodes during sexual activity, suggesting that long-term nitrate therapy may be safely switched to trimetazidine therapy when therapy for erectile dysfunction is required.
Giuseppe M C Rosano; Giuseppe Marazzi; Roberto Patrizi; Elena Cerquetani; Cristiana Vitale; Maurizio Volterrani; Massimo Fini; Giuseppe Mercuro
Related Documents :
9555559 - Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years...
17949529 - Predictability of irritative voiding symptoms following photoselective laser vaporizati...
759469 - Preservation of sexual potency in prostatic cancer patients after 125i implantation.
18568239 - Is the ability to perform transurethral resection of the prostate influenced by the sur...
18279929 - Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing ...
10851329 - Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive s...
22339789 - Does the magnetic anal sphincter device compare favourably with sacral nerve stimulatio...
9850259 - Visual function and patient satisfaction after macular hole surgery.
1349999 - Shockwave lithotripsy of salivary duct stones.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  95     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-01-26     Completed Date:  2005-03-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  327-31     Citation Subset:  AIM; IM    
Department of Medical Sciences, Cardiovascular Research Unit, San Raffaele, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Cross-Over Studies
Double-Blind Method
Drug Therapy, Combination
Electrocardiography, Ambulatory
Erectile Dysfunction / drug therapy*
Middle Aged
Myocardial Ischemia / prevention & control*
Nitrates / therapeutic use
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use*
Treatment Outcome
Trimetazidine / therapeutic use*
Vasodilator Agents / therapeutic use*
Reg. No./Substance:
0/Nitrates; 0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 139755-83-2/sildenafil; 5011-34-7/Trimetazidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of mental stress-induced myocardial ischemia in coronary artery disease patients with ver...
Next Document:  Association of anemia with diastolic dysfunction among patients with coronary artery disease in the ...